title: Show me the evidence!
abstract: For payers, evaluation of biologic therapies is a challenge. Funding is a roadblock to head-to-head studies. As the number of biologics and their indications expand, the risk is that a lack of objective evidence will lead to adoption of conservative review policies.
authors: Mark
authors: M
authors: Hagland